BTIG raises CareDx price target to $45, maintains Buy
BTIG analyst Mark Massaro maintains a Buy rating on CareDx and raises the price target to $45 from $28, signaling a positive outlook for the NASDAQ-listed company.
*this image is generated using AI for illustrative purposes only.
BTIG analyst Mark Massaro has maintained a Buy rating on CareDx and raised the price target to $45 from the previous $28. The revised target indicates a more optimistic valuation for the company's stock.
Rating and Target Details
The analyst's decision to upgrade the price target comes as CareDx continues to navigate its market position. The new target of $45 represents a significant increase from the prior estimate of $28.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $28 |
| New Price Target | $45 |
CareDx, listed on NASDAQ under the ticker CDNA, is the subject of this updated coverage. The Buy rating suggests confidence in the company's potential for growth.
What specific factors or market trends drove BTIG to nearly double the price target for CareDx?
How might CareDx's recent performance or product pipeline contribute to achieving this new valuation?
Could this price target increase signal a broader positive shift in the transplant diagnostics market?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
